2020
Proton-Based Chemoradiotherapy—What Level of Evidence Is Necessary to Justify Its Widespread Use?
Park HS, Yu JB. Proton-Based Chemoradiotherapy—What Level of Evidence Is Necessary to Justify Its Widespread Use? JAMA Oncology 2020, 6: 246-247. PMID: 31876903, DOI: 10.1001/jamaoncol.2019.4875.Peer-Reviewed Original Research
2016
Promoting the Appropriate Use of Advanced Radiation Technologies in Oncology: Summary of a National Cancer Policy Forum Workshop
Smith G, Ganz P, Bekelman J, Chmura S, Dignam J, Efstathiou J, Jagsi R, Johnstone P, Steinberg M, Williams S, Yu J, Zietman A, Weichselbaum R, Shih Y. Promoting the Appropriate Use of Advanced Radiation Technologies in Oncology: Summary of a National Cancer Policy Forum Workshop. International Journal Of Radiation Oncology • Biology • Physics 2016, 97: 450-461. PMID: 28011046, PMCID: PMC6044722, DOI: 10.1016/j.ijrobp.2016.10.042.Peer-Reviewed Original ResearchMeSH KeywordsCosts and Cost AnalysisDecision MakingDiffusion of InnovationHumansNational Academies of Science, Engineering, and Medicine, U.S., Health and Medicine DivisionNeoplasmsProgram EvaluationProton TherapyRadiation OncologyRadiotherapyRadiotherapy, Intensity-ModulatedResearch PersonnelTechnology, RadiologicUnited StatesConceptsRadiation oncology communityRadiation oncology treatmentsRadiation oncologyAdvanced radiation technologiesOncology communityOncological treatmentNational Cancer Policy Forum of the National Academies of SciencesNational Cancer Policy ForumPractice of radiation oncologyRadiation oncology practiceProspective registry dataCancer care decisionsGeneration of scientific evidenceRadiation therapyScientific evidenceEvidence-based effortsComparative effectiveness dataCancer careClinical effectsCare decisionsQuality benchmark dataDe-adoptionRegistry dataThe National Academy of SciencesOncology practiceEmerging Technologies and Techniques in Radiation Therapy
Magnuson W, Mahal A, Yu J. Emerging Technologies and Techniques in Radiation Therapy. Seminars In Radiation Oncology 2016, 27: 34-42. PMID: 27986210, DOI: 10.1016/j.semradonc.2016.08.004.Peer-Reviewed Original ResearchConceptsStereotactic body radiotherapyHigh-dose-rateProton beam radiationRadiation therapyProstate cancerHigh-dose-rate (HDR) brachytherapyHigh-risk prostate cancer patientsHigh-risk prostate cancerTreatment of prostate cancerPartial gland treatmentProstate-directed therapyRegional radiation therapyLow-risk diseaseBeam radiationProstate cancer patientsDeliver radiationImprove cancer controlHigh-intensity focused ultrasoundFocal therapyTherapeutic modalitiesRadiation treatmentCancer patientsCancer controlTherapyReduced toxicityNational trends and determinants of proton therapy use for prostate cancer: A National Cancer Data Base study
Mahal B, Chen Y, Efstathiou J, Muralidhar V, Hoffman K, Yu J, Feng F, Beard C, Martin N, Orio P, Nguyen P. National trends and determinants of proton therapy use for prostate cancer: A National Cancer Data Base study. Cancer 2016, 122: 1505-1512. PMID: 26970022, DOI: 10.1002/cncr.29960.Peer-Reviewed Original ResearchConceptsProton therapy useProstate cancerProton therapyTherapy useIncreasing use of proton therapyMultivariable adjustmentUse of proton therapyNational Cancer Data BaseLong-term follow-upExternal beam radiotherapyMultivariate logistic regression analysisHigh-grade diseaseNonmetastatic prostate cancerFactors associated with receiptNationwide cancer registryLogistic regression analysisBeam radiotherapyDefinitive therapyOncological therapyNonacademic centersTreated patientsClinical factorsFollow-upProstateCancer Registry
2013
Proton radiotherapy for prostate cancer: how did we get here, and where do we go from here?
Yu J, Efstathiou J, Bekelman J. Proton radiotherapy for prostate cancer: how did we get here, and where do we go from here? Oncology 2013, 27: 1293-4. PMID: 24624550.Peer-Reviewed Original Research